CPT1A, SCD and FASN may form an adjustable lipid metabolism enhancing pathway with CPT1A as the center, which plays a key synergistic role in the development of paclitaxel resistance in ovarian cancer. This evidence concerns the gene CPT1A and ovarian carcinoma.